Jun. 12 at 11:37 AM
$ANVS Zooming out. BMS spending
$14B on Karuna's schizophrenia treatment shows what the market pays for clean oral CNS drugs. Buntanetap sits on vastly superior neurodegenerative economics:
Massive Scale: The addressable market for Alzheimer's vastly outstrips schizophrenia. Demographic shifts create an entirely different tier of commercial volume.
Defensive Moats: Big Pharma is starved for clean, late-stage oral CNS assets. To protect their franchises and keep candidates away from rivals, they pay incredible premiums for defensive acquisitions.
Platform Scope: Unlike narrow psychiatric drugs, buntanetap targets multiple neurotoxic proteins. This creates parallel indications for Parkinson's (PD) and Parkinson's Dementia (PDD) alongside AD.
If a single-use psychiatric pill commands
$14B, an oral asset with validated signals in true p-Tau AD plus PD/PDD is a generational disconnect.
$40 Billion? What is the value?
$BIIB $LLY
